Dual targeting could deepen responses to VEGFR TKIs, convert β‐catenin–driven “cold” tumours into ICB‐sensitive ones, and complement HIF‐2α inhibitors like belzutifan. The gene discussed is EPAS1; the disease is neoplasm.